Výsledky vyhledávání

EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF EZETIMIBE IN PRIMARY HYPERCHOLESTEROLAEMIA: A POOLED ANALYSIS FROM TWO CONTROLLED PHASE III CLINICAL STUDIES

Autor: R H, Knopp, C A, Dujovne, A, Le Beaut, L J, Lipka, R, Suresh, E P, Veltri

Publikováno v: International Journal of Clinical Practice. 57:363-368

Ezetimibe is a novel cholesterol absorption inhibitor that blocks intestinal absorption of dietary and biliary cholesterol. Data from 1719 patients who participated in two multicentre, double-blind studies of ezetimibe were pooled to evaluate the dru

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf7c2218e355db389a07cd0701343514
https://doi.org/10.1111/j.1742-1241.2003.tb10508.x

Zobrazit plný text záznamu

The automatic implantable cardioverter-defibrillator. Long-term clinical experience and outcome at a hospital without an open-heart surgery program

Autor: T J, Cohen, P R, Reid, M M, Mower, M, Mirowski, D, Aarons, J, Juanteguy, E P, Veltri

Publikováno v: Archives of Internal Medicine. 152:65-69

From November 1982 through April 1989, 111 patients with refractory sustained ventricular tachycardia/fibrillation had the automatic cardioverter-defibrillator implanted at our institution, the first community hospital involved in implantation of suc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26a332e03346eb238eb9aa66fd4e94ea
https://doi.org/10.1001/archinte.152.1.65

Zobrazit plný text záznamu

Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia

Autor: C M, Ballantyne, L J, Lipka, P T, Sager, J, Strony, J, Alizadeh, R, Suresh, E P, Veltri

Publikováno v: International journal of clinical practice. 58(7)

Long-term safety and tolerability of ezetimibe plus atorvastatin (EZE + ATV) coadministration therapy were compared to those of ATV monotherapy in patients with primary hypercholesterolaemia. Upon completion of a 12 week randomised, double-blind, pla

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d49e9771235c93953e466e968b25720a
https://pubmed.ncbi.nlm.nih.gov/15311720

Zobrazit plný text záznamu

Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die?

Autor: C M, Pratt, A J, Camm, W, Cooper, P L, Friedman, D J, MacNeil, K M, Moulton, B, Pitt, P J, Schwartz, E P, Veltri, A L, Waldo

Publikováno v: The American journal of cardiology. 81(7)

The Survival With ORal D-sotalol (SWORD) trial tested the hypothesis that the prophylactic administration of oral d-sotalol would reduce total mortality in patients surviving myocardial infarction (MI) with a left ventricular ejection fraction (LVEF)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::0417b469cc3d42244609636dfef75166
https://pubmed.ncbi.nlm.nih.gov/9555777

Zobrazit plný text záznamu

Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol

Autor: A L, Waldo, A J, Camm, H, deRuyter, P L, Friedman, D J, MacNeil, J F, Pauls, B, Pitt, C M, Pratt, P J, Schwartz, E P, Veltri

Publikováno v: Lancet (London, England). 348(9019)

Left ventricular dysfunction after myocardial infarction is associated with an increased risk of death. Other studies have suggested that a potassium-channel blocker might reduce this risk with minimal adverse effects. We investigated whether d-sotal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8a7f34e63853735a1f8495a75284adeb
https://pubmed.ncbi.nlm.nih.gov/8950921

Zobrazit plný text záznamu

Long-Term Clinical Results with the Implantable Defibrillator

Autor: R. Lewis, E. P. Veltri, Lawrence S.C. Griffith, G. Tomaselli, T. Guarnieri, J. M. Juanteguy, L. Watkins

Publikováno v: The Implantable Cardioverter/Defibrillator ISBN: 9783642765773

Sudden cardiac death is the leading cause of cardiac mortality in patients with heart disease. Approximately 400000 such deaths occur in the United States alone each year [1], It has been established that the vast majority of sudden cardiac deaths ar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::24c807a053980df45ff3b25e4fe7c972
https://doi.org/10.1007/978-3-642-76575-9_10

Zobrazit plný text záznamu

Mexiletine-associated left ventricular dysfunction: a case study

Autor: S L, Ballas, K L, Baughman, L S, Griffith, E P, Veltri

Publikováno v: Maryland medical journal (Baltimore, Md. : 1985). 40(6)

Mexiletine is a lidocaine analogue used in the treatment of symptomatic ventricular arrhythmias. However, in selected individuals with baseline diminished left ventricular function, it may possess clinically significant negative inotropic effects.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c036ab7d26943669b385adc77102e665
https://pubmed.ncbi.nlm.nih.gov/1861579

Zobrazit plný text záznamu

The efficacy of amiodarone in the treatment of refractory nonsustained ventricular tachycardia

Autor: S L, Ballas, E P, Veltri

Publikováno v: Maryland medical journal (Baltimore, Md. : 1985). 40(6)

Amiodarone is very effective in suppressing refractory nonsustained ventricular tachycardia. Efficacy can be assessed after one week of therapy with continued long-term response in the vast majority of patients.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::230c06b92e1ba957656710dbcb9986b9
https://pubmed.ncbi.nlm.nih.gov/1861575

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání